William Blair cut shares of Natus Medical (NASDAQ:BABY) from an outperform rating to a market perform rating in a report published on Monday, MarketBeat.com reports.

Several other equities research analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Natus Medical from a hold rating to a buy rating and set a $45.00 price target on the stock in a research note on Tuesday, October 24th. BidaskClub downgraded shares of Natus Medical from a hold rating to a sell rating in a research report on Saturday, December 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. The company has an average rating of Hold and an average price target of $46.50.

Natus Medical (NASDAQ:BABY) traded down $1.40 during trading on Monday, reaching $29.00. 1,964,891 shares of the company traded hands, compared to its average volume of 1,104,200. Natus Medical has a 12-month low of $28.85 and a 12-month high of $43.60. The stock has a market cap of $903.47, a P/E ratio of -483.33 and a beta of 0.84. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.21 and a quick ratio of 3.36.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.02. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The firm had revenue of $122.60 million for the quarter, compared to the consensus estimate of $122.41 million. During the same quarter in the previous year, the firm posted $0.39 EPS. The firm’s quarterly revenue was up 34.9% on a year-over-year basis. sell-side analysts predict that Natus Medical will post 1.74 earnings per share for the current year.

In other news, VP Dong Chune Christopher Chung sold 12,642 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $42.91, for a total value of $542,468.22. Following the completion of the sale, the vice president now owns 141,414 shares of the company’s stock, valued at approximately $6,068,074.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William M. Moore sold 5,000 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $41.01, for a total transaction of $205,050.00. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Natus Medical by 0.6% in the 2nd quarter. BlackRock Inc. now owns 4,149,535 shares of the medical equipment provider’s stock worth $154,779,000 after purchasing an additional 25,340 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Natus Medical by 2.9% in the 2nd quarter. Vanguard Group Inc. now owns 2,341,546 shares of the medical equipment provider’s stock valued at $87,340,000 after buying an additional 66,676 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Natus Medical by 3.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,604,876 shares of the medical equipment provider’s stock valued at $60,183,000 after buying an additional 51,938 shares during the period. Daruma Capital Management LLC boosted its holdings in shares of Natus Medical by 13.1% in the 2nd quarter. Daruma Capital Management LLC now owns 1,470,839 shares of the medical equipment provider’s stock valued at $54,862,000 after buying an additional 169,890 shares during the period. Finally, State Street Corp boosted its holdings in shares of Natus Medical by 5.7% in the 2nd quarter. State Street Corp now owns 856,576 shares of the medical equipment provider’s stock valued at $31,946,000 after buying an additional 45,918 shares during the period. 99.94% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.watchlistnews.com/natus-medical-baby-lowered-to-market-perform-at-william-blair/1800453.html.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with Analyst Ratings Network's FREE daily email newsletter.